Prevencio Announces National Medicare Pricing for Company’s Three AI-Powered HART Cardiac Blood Tests

Newly Assigned Rates Further Validate Commercial Value of the HART Tests

Prevencio,The AI-Powered Cardiac Blood Test Company, announced the Centers for Medicare & Medicaid Services (CMS) has set a National Medicare payment rate of $390.75 for each of the Company’s three lead proprietary HART cardiac blood tests. The payment rates went into effect January 1, 2023, for Current Procedural Terminology (CPT) b****** codes 0308U (for CADhs), 0309U (for HART CVE), and 0310U (for HART KD).

Data Science News: Mosaic Data Science Develops Innovative AI-Text Generation Tool That Summarizes Content for Specific Audiences

“Building on Medicare’s pricing determination, we will work with commercial, self-insured, and governmental insurance programs, including Medicare and Medicaid, to provide patients with broader access to these important cardiac tests.”

HART CADhs determines whether an adult patient has obstruction of the heart arteries and is at imminent risk of a heart attack, whereas HART CVE improves identification for a patient’s short-to-intermediate risk of heart attack, stroke, or cardiac death. HART KD is the only available test to diagnose whether a child has Kawasaki disease.

“As cardiovascular disease is the leading cause of death in adults in the U.S., there is a tremendous need for both HART CVE and HART CADhs. The Medicare-determined price is additional evidence of the value of HART testing and is an important step in our commercial strategy to establish the HART reimbursement framework,” said Rhonda F. Rhyne, President & Chief Executive Officer of Prevenico. “Building on Medicare’s pricing determination, we will work with commercial, self-insured, and governmental insurance programs, including Medicare and Medicaid, to provide patients with broader access to these important cardiac tests.”

Data Science News: Mosaic Data Science Develops Innovative AI-Text Generation Tool That Summarizes Content for Specific Audiences

Cardiovascular disease is a global public health epidemic, with 19 million deaths annually. In the U.S., it is the leading cause of death and kills more people than all cancers combined. Cardiovascular disease is also an expensive disease, accounting for more than $378 billion annually in the U.S.

Prevencio is committed to providing clinicians with safer, highly accurate, and more affordable ways to identify the tens of millions of patients at risk for adverse cardiac events. HART tests are valuable for both hospitalized patients and outpatients.

AI Insights : XAPP AI Achieves AWS Conversational AI Competency Distinction

 [To share your insights with us, please write to sghosh@martechseries.com]